942 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Recruiting Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Conditions: Non-Small Cell Lung Cancer;   Leptomeningeal Metastases;   Brain Metastases
Intervention: Drug: Tesevatinib
8 Not yet recruiting Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Nivolumab;   Drug: Docetaxel
9 Not yet recruiting A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Part 1 (Dose Escalation): JNJ-61186372;   Drug: Part 2 (Dose Expansion): JNJ-61186372
10 Recruiting Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Condition: Non-small Cell Lung Cancer Starting Anti-PD1/PDL1 Therapy
Intervention: Radiation: [18F]fluoroglucose(FDG)
11 Recruiting TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
Condition: Carcinoma, Small Cell
Intervention: Drug: ARQ197
12 Not yet recruiting Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Conditions: Non-small Cell Lung Cancer;   Advanced Solid Tumor
Interventions: Drug: Stereotactic body radiotherapy;   Drug: Pembrolizumab
13 Recruiting A Prospective Multi-center Phase III Randomized Controlled Trial
Condition: Carcinoma,Non-Small-Cell Lung
Interventions: Drug: cisplatin and pemetrexed;   Drug: nadaplatin+pemetrexed
14 Not yet recruiting Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed With Surgery
Condition: Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Procedure: Computed Tomography;   Drug: Docetaxel;   Radiation: Fludeoxyglucose F-18;   Drug: Gemcitabine Hydrochloride;   Drug: Pemetrexed Disodium;   Procedure: Positron Emission Tomography
15 Recruiting Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer;   Metastatic Carcinoma
Interventions: Drug: temozolomide;   Radiation: prophylaxis cranial radiotherapy
16 Recruiting Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Docetaxel;   Drug: Pemetrexed
17 Not yet recruiting Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
Condition: Stage I Non-Small Cell Lung Cancer
Interventions: Drug: Atezolizumab;   Radiation: Stereotactic Body Radiation Therapy
18 Recruiting 18F-FSPG PET/CT for Cancer Patients on Therapy
Conditions: B-Cell Neoplasm;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Renal Cell Cancer;   Progesterone Receptor Negative;   Stage III Mesothelioma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 L-glutamate Derivative BAY94-9392;   Procedure: Positron Emission Tomography;   Procedure: Magnetic Resonance Imaging
19 Not yet recruiting Afatinib in NSCLC With HER2 Mutation
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib;   Drug: paclitaxel
20 Not yet recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years